Analysts Set Surgery Partners, Inc. (NASDAQ:SGRY) Target Price at $27.11

Surgery Partners, Inc. (NASDAQ:SGRY) has earned a consensus rating of “Moderate Buy” from the ten brokerages that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $27.1111.

Several research firms have recently weighed in on SGRY. UBS Group dropped their price objective on shares of Surgery Partners from $34.00 to $29.00 and set a “buy” rating for the company in a report on Thursday, November 13th. Royal Bank Of Canada dropped their price target on Surgery Partners from $35.00 to $31.00 and set an “outperform” rating for the company in a report on Tuesday, November 11th. JPMorgan Chase & Co. cut their price objective on Surgery Partners from $27.00 to $20.00 and set a “neutral” rating for the company in a research report on Monday, November 24th. Cantor Fitzgerald restated an “overweight” rating and set a $36.00 target price on shares of Surgery Partners in a report on Tuesday, October 7th. Finally, Mizuho lowered their target price on Surgery Partners from $22.00 to $19.00 and set an “outperform” rating for the company in a research note on Thursday, December 18th.

Surgery Partners Stock Performance

Surgery Partners stock opened at $15.65 on Wednesday. The firm has a market capitalization of $2.02 billion, a P/E ratio of -11.51 and a beta of 1.93. The stock has a fifty day moving average price of $17.66 and a two-hundred day moving average price of $20.40. Surgery Partners has a 52-week low of $14.94 and a 52-week high of $26.16. The company has a debt-to-equity ratio of 1.10, a current ratio of 1.88 and a quick ratio of 1.72.

Surgery Partners (NASDAQ:SGRY) last posted its earnings results on Monday, November 10th. The company reported $0.13 earnings per share for the quarter, missing the consensus estimate of $0.19 by ($0.06). Surgery Partners had a positive return on equity of 2.41% and a negative net margin of 5.21%.The firm had revenue of $821.50 million during the quarter, compared to the consensus estimate of $823.55 million. During the same period in the previous year, the company posted $0.19 EPS. The firm’s revenue for the quarter was up 6.6% compared to the same quarter last year. As a group, analysts anticipate that Surgery Partners will post 0.67 EPS for the current fiscal year.

Hedge Funds Weigh In On Surgery Partners

Institutional investors have recently modified their holdings of the stock. AlphaQuest LLC lifted its position in shares of Surgery Partners by 112.0% during the first quarter. AlphaQuest LLC now owns 1,058 shares of the company’s stock worth $25,000 after purchasing an additional 559 shares in the last quarter. Jones Financial Companies Lllp raised its position in Surgery Partners by 313.1% in the 3rd quarter. Jones Financial Companies Lllp now owns 1,227 shares of the company’s stock worth $27,000 after purchasing an additional 930 shares during the last quarter. Caitong International Asset Management Co. Ltd lifted its holdings in Surgery Partners by 45,640.0% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,287 shares of the company’s stock worth $49,000 after buying an additional 2,282 shares in the last quarter. PNC Financial Services Group Inc. boosted its position in Surgery Partners by 128.4% in the 3rd quarter. PNC Financial Services Group Inc. now owns 2,702 shares of the company’s stock valued at $58,000 after buying an additional 1,519 shares during the last quarter. Finally, FNY Investment Advisers LLC bought a new position in Surgery Partners in the 2nd quarter valued at $115,000.

Surgery Partners Company Profile

Surgery Partners, Inc operates as a healthcare services provider specializing in the management and ownership of ambulatory surgery centers, surgical hospitals and multispecialty rehabilitation hospitals across the United States. Through its network of facilities, the company coordinates and delivers a broad range of outpatient surgical procedures in specialties such as orthopedics, ophthalmology, otolaryngology, gastroenterology, pain management and general surgery. Its integrated platform offers ancillary services including on-site imaging, laboratory testing, infusion therapy and physical, occupational and speech rehabilitation.

Since its establishment in 2010 and subsequent public listing in 2015, Surgery Partners has focused on strategic partnerships with physicians and health systems to expand access to cost-effective outpatient care.